Leerink Partnrs Comments on Alumis FY2029 Earnings

Alumis Inc. (NASDAQ:ALMS) – Leerink Partnrs issued their FY2029 earnings per share estimates for Alumis in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.61) for the year. The consensus estimate for Alumis’ current full-year earnings is ($8.45) per share.

A number of other research firms have also issued reports on ALMS. Oppenheimer initiated coverage on shares of Alumis in a research note on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Robert W. Baird started coverage on Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price for the company. Baird R W raised Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $26.00 price target on shares of Alumis in a report on Monday, January 6th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $27.57.

Alumis Price Performance

Alumis stock opened at $6.59 on Thursday. Alumis has a one year low of $6.29 and a one year high of $13.53. The stock’s 50 day moving average price is $7.93 and its 200 day moving average price is $10.30.

Institutional Trading of Alumis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Alumis in the 2nd quarter worth approximately $3,376,000. Towerview LLC lifted its stake in Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after purchasing an additional 70,000 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Alumis in the third quarter worth $1,160,000. BNP Paribas Financial Markets acquired a new position in Alumis in the third quarter worth $27,000. Finally, MetLife Investment Management LLC bought a new stake in Alumis during the third quarter valued at $89,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.